Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form 8-K

TETRAPHASE PHARMACEUTICALS INC Form 8-K December 21, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 15, 2015

Tetraphase Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware (State or other jurisdiction

001-35837 (Commission **20-5276217** (IRS Employer

of incorporation)

File Number)

Identification No.)

Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form 8-K

480 Arsenal Street, Suite 110,

Watertown, Massachusetts 02472 (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (617) 715-3600

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- "Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 (b). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 15, 2015 J. Craig Thompson resigned his position as chief operating officer of Tetraphase Pharmaceuticals, Inc. (the Company) in order to pursue other interests. Mr. Thompson s resignation is effective December 31, 2015.

Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By: /s/ Maria D. Stahl
Date: December 21, 2015

By: /s/ Maria D. Stahl

Senior Vice President, General Counsel